

Express Mail No. EV 303490394 US
Docket No. NEX86/PCT-US

IN THE UNITED STATES RECEIVING OFFICE

APPLICANT: HICKE ET AL.
SERIAL NO.: 10/031,193
FILED: January 31, 2002
FOR: TENACIN-C NUCLEIC ACID
LIGANDS

EXAMINER: FORMAN, BJ
ART UNIT: 1634
CONFIRMATION NO: 6209

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being submitted under 37 CFR § 1.97(c). This Statement is filed after three months from the filing date of the national application, after three months from the date of entry into national stage under 37 CFR § 1.491, after the mailing of a first Office Action on the merits, or after the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114, but before the mailing date of any of:

- (a) a final action under 37 CFR § 1.113;
- (b) a notice of allowance under 37 CFR § 1.311; or
- (c) an action that otherwise closes prosecution in the application.

This Statement is accompanied by a check for \$180 in accordance with 37 CFR §§1.97(c) and 1.17(p). The undersigned hereby authorizes the charging of any deficiency of fees submitted herewith to Deposit Account No. 19-5117.


06/03/2004 MMEKONEN 00000143 10031193
02-FC:1806 180.00-OP

06/03/2004 MMEKONEN 00000144 10031193
01 FC:1806 180.00 OP

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: Jun 1, 2004



Steven N. Hird, #51,112
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

SNH/dsm

cc: Ute Kilger, John Harre,
Vanessa Appleby, Mark Bosse

S:\CLIENT FOLDERS\GILEAD (FORMERLY NEXSTAR)\NEX86\PCT\US\SUPPIDS2.DOC

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO. NEX 86/PCT-US	SERIAL NO. 10/031193
	APPLICANT HICKE ET AL.	
	FILING DATE JANUARY 31, 2002	GROUP 6209



U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB-CLS	FILE DATE
	AA						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB-CLS	TRANS ?
	AE						
	AG						
	AH						
	AI						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AJ	Bourdon et al., (1984) <i>Anticancer Res.</i> 4(3):133-40
		Clarke, (1996) <i>Breast Cancer Res Treat.</i> 39:69-86
	AK	Heikinheimo et al., (1991) <i>Virchows Arch B Cell Pathol Incl Mol Pathol.</i> 61(2):101-9
	AL	Hjelstuen, (1995) <i>Analyst.</i> 120: 863-866
	AM	Ishihara et al., (1995) <i>Clin. Cancer Res.</i> 1:1035-1041
	AN	Jahkola et al., (1998) <i>Eur. J. Cancer</i> 34:1687-1692
	AO	Jahkola et al., (1998) <i>Br. J. Cancer</i> 78:1507-1513
	AP	Reardon et al., (2002) <i>J Clin Oncol.</i> 20(5):1389-97
	AQ	Rofstad & Lyng, (1996) <i>Mol Med Today.</i> 2:394-403
	AR	Schnyder et al., (1997) <i>Int J Cancer.</i> 17;72(2):217-24
	AS	Schold et al., (1993) <i>Invest Radiol.</i> 28(6):488-96
	AT	Soini et al., (1992) <i>Virchows Arch A Pathol Anat Histopathol.</i> 421(3):217-22
	AU	Stamp, <i>J Pathol.</i> (1989) Nov;159(3):225-9
	AV	Thompson et al., (1998) <i>Biochim Biophys Acta.</i> 1400(1-3):301-19
	AW	Tiitta et al., (1993) <i>Virchows Arch B Cell Pathol Incl Mol Pathol.</i> 63(5):283-7
	AX	Vollmer et al., (1990) <i>Lab Invest.</i> 62(6):725-30
	AY	Yamada et al., (1992) <i>Liver</i> , 12(1):10-6
	AZ	Zalutsky et al., (1989) <i>Cancer Res.</i> 15;49(10):2807-13
	AAA	
EXAMINER		
DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		